Nasdaq Moves to Delist Jupiter Neurosciences; Company to Appeal
JUNS is trading near its 52-week low of $4.101 (0.5% above the low) on light trading volume (0.2× avg).
Summary
Nasdaq has determined to delist Jupiter Neurosciences after the company failed to meet the $35M market value listing requirement. The company will appeal, and separately confirmed it has regained compliance with the $1.00 minimum bid price rule.
Key Events · Legal and Risk Events · JUNS
-
Nasdaq Delisting Determination
Nasdaq Staff determined to delist JUNS from The Nasdaq Capital Market for failure to regain compliance with the $35M market value requirement (Rule 5550(b)(2)) by August 25, 2026.
-
Appeal and Stay
The company intends to timely appeal by requesting a hearing before the Nasdaq Hearings Panel, which is expected to stay further action pending the final determination; no assurance of success.
-
Bid Price Compliance Regained
For 10 consecutive business days from August 13-26, 2026, the closing bid price was at least $1.00, regaining compliance with Rule 5550(a)(2); that matter is now closed.
-
Distressed Financial Context
The delisting comes with the stock near its 52-week low, a market cap of roughly $5.1M, and a previously disclosed going-concern warning and material weakness in internal controls.
Analysis · JUNS · Life Sciences
Nasdaq has formally determined to delist Jupiter Neurosciences' common stock after the company failed to regain compliance with the $35 million market value requirement by the August 25, 2026 deadline. The company intends to appeal, which would stay the delisting pending a hearing, but there is no assurance the appeal will succeed. Separately, the company regained compliance with the $1.00 minimum bid price rule, closing that matter. The delisting determination is a critical event for a company already trading near its 52-week low with a market cap of roughly $5 million and a going-concern warning on file.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JUNS was trading at $4.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $4.10 to $137.96. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.